Jacobi Capital Management’s Myriad Genetics MYGN Stock Holding History

Jacobi Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-38	Closed	-$1K	–	980
2021 Q3	$1K	Hold	38	–	–	﹤0.01%	1401
2021 Q2	$1K	Hold	38	–	–	﹤0.01%	1346
2021 Q1	$1K	Hold	38	–	–	﹤0.01%	1316
2020 Q4	$1K	Hold	38	–	–	﹤0.01%	1246
2020 Q3	$0	Hold	38	–	–	﹤0.01%	1280
2020 Q2	$0	Buy	+38	New	+$540	﹤0.01%	1254
2020 Q1	–	Sell	-40	Closed	-$845	–	1180
2019 Q4	$1K	Hold	40	–	–	﹤0.01%	1021
2019 Q3	$1K	Hold	40	–	–	﹤0.01%	1004
2019 Q2	$1K	Hold	40	–	–	﹤0.01%	997
2019 Q1	$1K	Hold	40	–	–	﹤0.01%	942
2018 Q4	$1K	Hold	40	–	–	﹤0.01%	918
2018 Q3	$2K	Hold	40	–	–	﹤0.01%	897
2018 Q2	$1K	Hold	40	–	–	﹤0.01%	978
2018 Q1	$1K	Buy	+40	New	+$1.35K	﹤0.01%	944
2016 Q4	–	Sell	-600	Closed	-$12K	–	671
2016 Q3	$12K	Hold	600	–	–	0.01%	448
2016 Q2	$19K	Buy	+600	New	+$20.8K	0.01%	353

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Jacobi Capital Management's MYGN Position: Q4 2021 in Review

Jacobi Capital Management sold out of Myriad Genetics (MYGN) in Q4 2021, closing a stake of 38 shares — an estimated $1K sold.

Jacobi Capital Management first reported a position in MYGN in Q2 2016 and held it in 16 quarters. The position peaked at $19K in Q2 2016. 197 funds tracked by Wall St. Rank hold MYGN as of Q4 2021.

Jacobi Capital Management reported no remaining Myriad Genetics position as of Q4 2021 after selling out during the quarter.
Jacobi Capital Management sold 38 Myriad Genetics shares in Q4 2021, an estimated $1K.
Jacobi Capital Management first reported a position in Myriad Genetics in Q2 2016 and held it in 16 quarters.
Jacobi Capital Management's Myriad Genetics position peaked at $19K in Q2 2016.
197 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2021.

Based on Jacobi Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.